Table 3 Cox proportional hazards models of mortality.

Variable	Univariable				Multivariable^a
	Hazard ratio	95% CI		p value	Hazard ratio	95% CI		p value
	Hazard ratio	Lower	Upper	p value	Hazard ratio	Lower	Upper	p value
Age, year	1.029	0.974	1.112	0.352
Sex, male	1.313	0.374	5.149	0.672
Pack-year of smoking	1.012	0.993	1.028	0.203
Clinical group of PH, 3 (vs. 1)	1.886	0.232	15.32	0.521
WHO functional class, 3–4 (vs. 1–2)	4.752	1.327	18.96	0.017	4.446	1.203	18.31	0.026
FVC, % pred	0.993	0.953	1.027	0.690
DL_CO, % pred	0.897	0.748	0.995	0.036	0.897	0.747	0.995	0.037
PaO₂ at rest, Torr	0.998	0.948	1.040	0.920
Distance in 6MWT	0.997	0.990	1.004	0.423
Minimum SpO₂ in 6MWT	0.957	0.844	1.069	0.438
TRPG, mmHg	1.013	0.986	1.043	0.352
mean PAP, mmHg	0.971	0.849	1.076	0.612
PVR, wood	0.946	0.666	1.399	0.767
Emphysematous lesion on HRCT, ≥ 10%	2.792	0.794	10.96	0.108
NT-ProBNP, pg/mL	1.001	0.999	1.002	0.099	1.001	0.999	1.002	0.110
Serum ANGP-1, high (vs. low)	1.781	0.468	8.458	0.404
Serum ANGP-2, high (vs. low)	7.716	1.414	143.2	0.015	6.063	1.099	112.9	0.037
LTOT, +	7.135	1.853	29.32	0.005	8.419	2.143	35.24	0.003
Steroids/immunosuppressants use, +/−	2.292	0.634	8.286	0.198
PG, PDE-5 antagonist, or ERA use, +/−	0.517	0.078	2.073	0.376

PH pulmonary hypertension, WHO world health organization, FVC forced vital capacity, DLCO diffusion lung capacity for carbon monoxide, 6MWT 6-min walk test, TRPG tricuspid regurgitation pressure gradient, PAP pulmonary arterial pressure, PVR pulmonary vascular resistance, HRCT high-resolution computed tomography, NT-ProBNP N-terminal pro brain natriuretic peptide, ANGP angiopoietin, LTOT long term oxygen therapy, PG prostaglandin, PDE phosphodiesterase, ERA endothelin receptor antagonist.
^aAge-adjusted multivariable models.

Quick links

Search